Objective: In stiff person syndrome (SPS), an antibody-mediated impaired c-aminobutyric acidergic (GABAergic) neurotransmission is believed to cause muscle stiffness and spasms. Most patients improve with GABA-enhancing drugs and intravenous immunoglobulin, but some respond poorly and remain disabled. The need for more effective therapy prompted a trial with the anti-CD20 monoclonal antibody rituximab. Methods: This was a placebo-controlled randomized trial of rituximab (2 biweekly infusions of 1g each). The primary outcome was a change in stiffness scores at 6 months. Secondary outcomes were changes in heightened-sensitivity and quality of life scores. Enrolling 24 patients was calculated to detect 50% change in stiffness scores. Results: Randomization was balanced for age, sex, disease duration, and glutamic acid decarboxylase autoantibody titers. No significant changes were noted at 6 months after treatment in all outcomes. Specifically, no differences were noted in the stiffness index, the primary outcome, or sensitivity scores, the secondary outcome, at 3 or 6 months. Quality of life scores improved significantly (p < 0.01) at 3 months in both groups, but not at 6 months, denoting an early placebo effect. Blinded self-assessment rating of the overall stiffness for individual patients revealed improvement in 4 patients in each group. At 6 months, improvement persisted in 1 patient in the placebo group versus 3 of 4 in the rituximab group, where these meaningful improvements were also captured by video recordings. Interpretation: This is the largest controlled trial conducted in SPS patients and demonstrates no statistically significant difference in the efficacy measures between rituximab and placebo. Rituximab's lack of efficacy could be due to a considerable placebo effect; insensitivity of scales to quantify stiffness, especially in the less severely affected patients; or drug effectiveness in only a small patient subset.
S
tiff person syndrome (SPS) is an immune-mediated disorder characterized by rigidity of the axial and proximal limb muscles, superimposed upon disabling spasms and heightened sensitivity to external stimuli. [1] [2] [3] Although thought to be rare, the disease is largely underdiagnosed. SPS responds to immunotherapies [3] [4] [5] and is frequently associated with other autoimmune diseases and autoantibodies. [1] [2] [3] [4] [5] More than 80% of SPS patients have high-titer antibodies against glutamic acid decarboxylase (GAD), the rate-limiting enzyme for the synthesis of c-aminobutyric acid (GABA), [1] [2] [3] [4] [5] [6] [7] [8] and up to 15% have antibodies to glycine receptor a-subunit. 9, 10 Although the causative link between SPS and these antibodies is still uncertain, several studies suggest that: (1) GAD activity and GABA synthesis are directly inhibited in vitro by anti-GAD specific IgG from SPS patients 11, 12 ; (2) anti-GAD antibodies are produced intrathecally, and they are associated with low GABA level in the brain and cerebrospinal fluid 2, 13, 14 ; (3) GAD immunization of animals under specific conditions
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induces GABAergic neuronal loss 15 ; (4) GABA-receptor associated protein IgG antibodies from GAD-positive patients inhibit the expression of GABA A receptors in cerebellar neurons 16 ; and (5) disease-specific monoclonal antibodies are able to impair GABAergic neurotransmission and affect behavior in laboratory animals. 17 Although the pathogenic role of anti-GAD antibodies needs further confirmatory evidence, 18, 19 their presence in > 80% of the patients suggests that B cells are activated and may participate in the disease, possibly exerting multiple immunoregulatory effects in the periphery or within the central nervous system (CNS), as proposed for other CNS disorders. 20, 21 Accordingly, a drug that affects B cells may be beneficial. SPS patients usually respond favorably to GABA-enhancing drugs and periodic infusions of intravenous immunoglobulin (IVIg), 4, 22, 23 but in many of them the improvement is modest or short-lived, necessitating the need for exploring other more specific therapies. Rituximab is a genetically engineered monoclonal antibody directed against CD20 that causes a swift and sustained depletion of B cells; the drug is promising in the treatment of several autoimmune neurological diseases, including multiple sclerosis. 20, 21 The sustained effect of rituximab in other antibody-mediated disorders prompted us to examine its efficacy in anti-GADpositive SPS patients.
Patients and Methods
Patient Recruitment, Randomization, and Exclusion Criteria
The study was conducted at the National Institutes of Health (NIH) under a cooperative research and development agreement (CRADA) between the National Institute of Neurological Diseases and Stroke (NINDS; M.C.D., principal investigator) and Genentech between 2003 and 2006. The trial was registered at ClinicalTrials.gov (NCT00050245) and was conducted under a protocol approved by the NINDS Institutional Review Board and after approval by the U.S. Food and Drug Administration of an Investigational New Drug application from the principal investigator. All patients were admitted to the NIH Clinical Center and signed an informed study consent. A total of 24 patients with confirmed diagnosis of SPS fulfilling previously established clinical criteria were enrolled. Patients were selected among >40 patients followed in the outpatient clinic at the NIH Clinical Center, as published in previous series, 1,2,13,14,22 but also from newly recruited patients specifically for this study. All patients were symptomatic, with a varying degree of stiffness and spasms, quantified according to the scales described previously 22 and below. All patients had high serum anti-GAD antibody titers (measured commercially), consistent with SPS. GAD titers were also measured and quantified blindly at the end of the study in serum samples taken before enrollment and at 6 months after treatment in the Neuroimmunology Unit, Medical School, University of Athens, using an enzyme-linked immunosorbent assay (ELISA) as reported. 24 Patients with previous history of B-cell or other type of malignancies, and those who had received any kind of immunosuppressive therapy over the 6-month period prior to enrollment, were excluded.
Randomization and Treatment Plan
Patients were allowed to continue receiving one of the nonimmunosuppressive drugs used to treat SPS, such as diazepam, gabapentin, or baclofen, but at the lowest possible dose that provided tolerable daily function. The doses of these drugs, lowered to the minimum specifically for the study, remained stable throughout the study and unchanged for 6 weeks prior to enrollment. Randomization was performed by the NIH pharmacy. After randomization, 2 biweekly intravenous cycles of 1g of rituximab or placebo (consisting of a normal saline solution) were administered. All patients were under continuous monitoring following standard safety guidelines, as previously described for our other rituximab trial. 25 Patients were premedicated with 650mg acetaminophen and 25mg diphenhydramine before infusions. Both drug and placebo were supplied by the NIH pharmacy and sent to the floor covered so that all investigators, assessors, evaluators, and nurses remained blinded to the study code. A data safety monitoring board was established to monitor safety.
Efficacy and Monitoring
Clinical efficacy was determined on the basis of changes in the stiffness index and heightened sensitivity scores, which measure clinical severity and have been validated and utilized in other trials, 22 at months 3 and 6 after the infusions. These scales measure the following:
DISTRIBUTION OF STIFFNESS INDEX. This validated index score was used as the study's primary outcome measure. The scale determines and quantifies stiffness as follows: 0, absent stiffness; 1, stiffness in face; 2, stiffness in arms; 3, stiffness in upper trunk; 4, stiffness in abdomen; 5, stiffness in lower trunk; 6, stiffness in legs. The presence of each item adds 1 point (maximum score 5 6). A 2.5-point decrease in the distribution of stiffness at month 6 was considered a sign of efficacy.
HEIGHTENED SENSITIVITY SCALE. This validated scaleused as a secondary outcome measure-determines and quantifies the events that trigger stiffness and spasms as follows: 1, noise-induced stiffness and cramps; 2, visually induced stiffness and cramps; 3, somatosensory-induced stiffness and cramps; 4, voluntary activity-induced spasms; 5, emotional upset and "stress"-induced spasms; 6, awakening due to nocturnal spasms; 7, untriggered cramps and spasms. The presence of each item adds 1 point (maximum score 5 7).
ANCILLARY OUTCOME MEASURES. To enhance the information obtained from the aforementioned scales, we used the following additional ancillary outcome measures.
Intensity of Stiffness. We utilized an examination-based, but empirical, stiffness severity scale that we called "overall stiffness intensity," rated 0 (absent), 1 (mild), 2 (moderate), or 3 (severe), combined with self-reported changes of stiffness, to appreciate the overall degree of stiffness at the end of the study. We reasoned that this might provide, in addition to the number of stiff areas noted above, some quantitative information on the overall stiffness severity.
Quality of Life Questionnaire. These scores were collected at baseline and in 3 subsequent measurements (on days 30, 90, and 180) following therapy (Supplementary Table 1 ).
Telephone Survey Questionnaire. Before breaking the study code, but several months after study completion, the patients were contacted on the phone by 2 of us (M.C.D. and B.M.) simultaneously, and were asked about the overall benefit they had experienced from the study drug using a standardized questionnaire. Specific questions in the questionnaire included the following: How did you rate your overall stiffness, on a scale from 1 (normal) to 10 (worst), at baseline and during the 6-month study period; When did improvement or deterioration start; How long did it last; and What is your status "now," referring to several months after study completion when the interview was conducted. This survey was felt useful given the subjective nature of some SPS symptoms, especially stiffness, and the inherent difficulty in quantifying them. The patients were also asked to guess whether they thought they had received the drug or placebo and to justify their reasoning.
Outcome Measures and Data Analysis
As per protocol, patient outcomes were evaluated on a continuous basis. The protocol was designed to test the superiority of rituximab compared to placebo. The primary outcome measure was a change in the stiffness index, and the secondary outcome was a change in heightened sensitivity at month 6. Based on our published data of stiffness index scores for untreated patients, 22 we assumed a variance of 0.83 using a repeatedmeasures (4 time periods) analysis of variance with Greenhouse-Geisser correlation; a total sample size of 24 patients (12 in each group) was deemed sufficient to provide the basis for detecting a change of 50% or greater with power > 0.80 and probability of type I error no more than 0.05. Accordingly, 24 patients were enrolled and randomized. Efficacy was based on the difference in scores from baseline to end of treatment employing an intention to treat analysis. Comparison of the differences in scores between the placebo-randomized patients and those randomized to rituximab was carried out employing the Wilcoxon signed-rank test for analysis.
Monitoring of Anti-GAD Antibody Titers
Anti-GAD antibody titers were monitored with an ELISA (Euroimmun, L€ ubeck, Germany) that was set up at the Neuroimmunology Unit, University of Athens after the trial, as described. 24 Anti-GAD titers were measured in samples taken before enrollment (baseline) and at month 6 following either rituximab or placebo infusion.
Results

Randomization and Baseline Evaluation
Twenty-four patients were enrolled; 12 were randomized to rituximab and 12 to placebo. Baseline characteristics were balanced between treatment groups regarding age, disease duration, GAD antibody titers, stiffness index, sensitivity scales, concomitant autoimmune diseases, and diabetes (Table) .
Clinical Evaluations
At baseline, the stiffness index was the same in both groups. One month after treatment, there was a nonsignificant reduction in the stiffness index in both groups; at 3 months, a reduction in stiffness was observed in the placebo group but the difference was not significant compared to rituximab; at 6 months, the stiffness index (the primary outcome measure) was equally reduced in both groups (Fig 1) . The heightened sensitivity index also did not capture any differences between the groups; some early worsening was observed in the placebo group, but the difference was not significant compared to rituximab. The quality of life index improved significantly (p < 0.01) in both groups at month 3, denoting an early strong placebo effect; at month 6, the scores were moving upward in the placebo group but continued to go down in the rituximab group, but the difference was not significant. The F statistic (with 1 and 18 degrees of freedom) probability values associated with the repeatedmeasure ANOVA were 0.559 for stiffness, 0.433 for hypersensitivity, and 0.486 for quality of life. For each of these 3 responses, there appears to be a placebo effect, as apparent in the figures. The following minor missing data that did not affect the results (even when the closest data were used) should be noted; in 1 placebo-randomized patient the baseline data and in another the 3-month data were missing; in the rituximab group, in 1 patient the stiffness index was missing for month 3 and for 2 others it was missing for month 6 (1 had dropped off the study at month 4).
OVERALL STIFFNESS INTENSITY SCORE. This scale, used as an ancillary measure to capture possible changes in the degree of stiffness, also failed to detect any difference between the 2 groups. Based on the examinationbased scores (0, absent; 1, mild; 2, moderate; 3, severe), combined with the question of whether the patients felt better or worse or had no response, the following information was obtained: (1) of the patients who felt better, experiencing mild-to-moderate improvement in their stiffness, 6 had received placebo and 4 rituximab; (2) 2 patients felt worse, both of whom had received placebo; and (3) of the patients who felt "no response," 8 had received rituximab and 4 placebo.
Effect of Rituximab on Anti-GAD Antibody Levels
A marked reduction in the anti-GAD titers was observed in the rituximab arm at month 6, but the effect was not statistically significant (p 5 0.0872, paired t test). There was no difference in titers pre-and postplacebo (p 5 0.6321; Fig 2) . Furthermore, 3 patients (2 in the FIGURE 2: Antibody titers before-and 6 months after administration of (A) rituximab or (B) placebo. Although the glutamic acid decarboxylase (GAD) titers are clearly reduced in the rituximab arm, the reduction was not significant compared to placebo. FIGURE 1: Graphic representation of (A) stiffness, (B) heightened sensitivity, and (C) quality of life (QoL) indexes. No statistically significance difference is noted not only for the stiffness index (the primary endpoint) but also for the other measures. It is of interest, however, that the QoL scales improved significantly at month 3 for both groups, denoting a strong early placebo effect. SEM 5 standard error of the mean.
placebo arm and 1 in the rituximab arm) were also positive for anti-glycine receptor antibodies, as reported previously. 9 No significant changes in the GAD antibody titers were observed in the 4 patients with a clinically observed response to rituximab, compared to the rest.
Assessment of Patients' Own Response to Therapy before Breaking the Study Code
TELEPHONE SURVEY QUESTIONNAIRE. Details of the patient's own assessment before and after completion of the study were clearly reflected in the telephone interview, conducted several months after completion of the study but before breaking the study code, using a standardized questionnaire. As shown in Supplementary Table 2 , no overall substantial differences were reported between the rituximab and the placebo group in any of the questions aimed to capture efficacy, quality of life, functional status, or side effects.
Plots of self-assessed stiffness rates for individual patients during the 6-month study period are shown in Figure 3 . Four patients on rituximab (#2, 12, 18, and 19 in Supplementary Table 2) reported clinical improvement in overall stiffness, starting 2 to 3 months after treatment initiation and peaking at 6 months; in some of these patients, video analysis also captured the improvements in gait and bodily functions (data not shown). Similarly, 4 patients on placebo (#3, 5, 20, and 22 in Supplementary Table 2 ) also reported clinical improvement in their overall stiffness, but in contrast to the rituximab group, these patients experienced the improvements somewhat earlier and in only 1 patient did improvement persist at 6 months.
The patients were also asked to guess whether they received rituximab or placebo. Three of 12 patients randomized to placebo stated that they received the drug and improved, 1 was uncertain, and 8 guessed correctly that they received placebo. Similar results were reported in the rituximab group; 7 patients felt they received placebo, 1 received the drug only because of a rash but without any change throughout the study, and 4 guessed correctly that they received rituximab and improved, providing clinical details (see Fig 3 and Supplementary  Table 2 ).
Discussion
This is the largest randomized controlled trial conducted in patients with SPS. The study demonstrated lack of efficacy of rituximab compared to placebo. In several other B-cell-mediated neurological disorders, such as multiple sclerosis, autoimmune encephalitis, and myasthenia gravis, rituximab seems effective or promising. 20, [25] [26] [27] [28] In contrast, in SPS, despite the presumed role of antibodies in disease pathogenesis, rituximab was not superior to placebo. The results are not necessarily in contrast to a few anecdotal reports [29] [30] [31] where rituximab was reported efficacious in SPS, because 4 of 12 patients in our series who received rituximab reported meaningful clinical improvements, which in some cases were captured by video recordings. There are several reasons for the noted lack of statistically significant efficacy in the present placebo-controlled study that may also shed light on the value of placebo in randomized trials. First, the study showed a strong placebo effect, as evidenced by the improvement observed in both groups, and supported by the patients' own assessment after completion of the study, despite being less prominent compared to rituximab (see Fig 3) . Although placebo effect is a factor in many placebo-controlled trials, it was very prominent in the present study, probably because of the subjective nature of the patients' symptomatology, the FIGURE 3: Scatter plots of self-reported clinical improvement or deterioration of the overall stiffness, rated 1 (best) to 10 (worst), in individual subjects at 3 time points. In the rituximab arm, 4 patients experienced improvement prominent at 6 months. In the placebo arm, some patients reported improvement, particularly within the first 3 months of the study, consistent with a placebo effect.
frequent fluctuations, and the underlying anxiety, which for some patients is pronounced, 32 creating a strong anticipatory effect. Fear and anxiety in several SPS patients exhibit a day-to-day variation that may aggravate stiffness and spasms and have an overall impact on assessing response to therapies. Second, the scales used may be still insensitive and, to a certain degree subjective, even when recorded by the same neurologist, as we did throughout the study. Although we had used the same validated scales to demonstrate efficacy of IVIg in SPS patients, 22 in the rituximab study we included patients with overall less severe symptomatology, so that the scales used might not have been sensitive enough to capture minor changes. Third, the degree of stiffness may fluctuate even from day to day, and is influenced, in addition to emotional stress, by various external factors difficult to control for. The advantage of the crossover trial design, which we used in the previous IVIG trial, 22 is that it mitigates the effect of such factors, because these fluctuations in the very same patient are probably balanced out during both treatment periods. Finally, rituximab may only help a subset of patients, as observed in the present study and documented by video analysis in some patients, implying that there is heterogeneity among SPS patients and larger patient numbers may be needed to reach statistical significance. A similar experience was noted in 2 prior trials with rituximab in patients with another rare disease, anti-myelin-associated glycoprotein (MAG) neuropathy. 25, 33 In both of these studies, no statistically significant effect was noted, but individual patients experienced an apparent or even dramatic benefit, suggesting that a per-patient assessment by objective functional scales or video recordings may have merit in small trials necessitated by disease rarity. Rituximab had no statistically significant effect on anti-GAD antibody titers, although titers were markedly reduced. This was not unexpected but still does not provide an explanation for the lack of clinical efficacy, because in SPS the serum antibody titers do not correlate with disease severity. The drug was well tolerated. Some infusion-related reactions were equally balanced in both groups, and none of the side effects was obvious or sufficiently distinct from the placebo to unblind the observers (see Supplementary Table 2 ). Similar observations were made in larger trials of rituximab in multiple sclerosis 20 and in anti-MAG demyelinating neuropathies. 25, 33 An obvious question is whether the outcome of this negative trial can be definitively interpreted as indicating that rituximab is ineffective in SPS patients, especially those with severe disease. Because in our series 4 patients with severe disease reported meaningful improvements, some of which were captured in video recordings, it seems logical to entertain the impression that the drug might be useful for a subset of patients who have failed previous therapies with GABA-enhancing drugs and IVIg; anecdotal reports support this view. [29] [30] [31] We have also witnessed an effect of rituximab in the SPS variant, progressive encephalomyelitis with rigidity and myoclonus, 34 when a patient positive for anti-glycine receptor antibodies dramatically improved after a series of rituximab infusions. Whether a second set of infusions 6 months later could have made a difference cannot be excluded, but in our experience with other neuromuscular diseases, such as myasthenia gravis and anti-MAG neuropathy, it seems unlikely that continuation of therapy will be of additional value if there is no convincing benefit 6 to 8 months after the first set of infusions. In 1 of the patients who dramatically improved (#12 in Supplementary Table 2 ), the improvement lasted 6 to 7 months (consistent with the mode of action of rituximab and the experience from other conditions 20, 21 ), prompting a request for a new infusion. The study, although well conducted, has a few inherent limitations. Even if the series represents the largest-ever controlled study in SPS, the number of patients may still be too small to establish efficacy using subjective and nonlinear scales. Analysis of video recordings may be helpful but not solely sufficient or without a subjective bias. This is especially pertinent when including patents with less severe disease, as we did in this study, where appreciation of small changes may be objectively difficult. Perhaps the newer anti-B-cell agents such as ocrelizumab, ofatumumab, or obinutuzumab as well as agents affecting B-cell regulatory functions, such as those directed against interleukin-6, may be more promising agents in SPS patients, as discussed. 21 Alternatively, the study results cannot exclude the possibility that SPS may be predominantly mediated by sensitized T cells rather than B cells and pathogenic autoantibodies, as has already been suggested. 3, 6 
